Literature DB >> 15743737

Correlation of HER-2 status with estrogen and progesterone receptors and histologic features in 3,655 invasive breast carcinomas.

Priti Lal1, Lee K Tan, Beiyun Chen.   

Abstract

We studied the inverse relationship between HER-2 and estrogen (ER) and progesterone (PR) receptors using HER-2 testing and correlated HER-2 status with histologic features in 3,655 unselected invasive breast carcinomas. Immunohistochemical analysis for ER, PR, and HER-2 and fluorescence in situ hybridization for HER-2 were performed. ER and PR expression were decreased significantly in HER-2+ tumors compared with HER-2- tumors (ER, 49.1% vs 78.17%; PR, 24.3% vs 53.13%). Even among HER-2+ tumors, the rate of ER or PR expression in high-grade tumors was significantly decreased compared with intermediate-grade tumors. HER-2 was positive in 10.87% of grade 2 and 27.84% of grade 3 ductal carcinomas and negative in all grade 1 ductal carcinomas. HER-2 overexpression or amplification essentially was limited to grades 2 and 3 ductal carcinomas and correlated inversely with ER or PR expression. Although ER or PR expression is decreased in HER-2+ tumors, a substantial proportion of them still express ER or PR.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15743737     DOI: 10.1309/YMJ3-A83T-B39M-RUT9

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  45 in total

Review 1.  Systems approaches to molecular cancer diagnostics.

Authors:  Shuyi Ma; Cory C Funk; Nathan D Price
Journal:  Discov Med       Date:  2010-12       Impact factor: 2.970

2.  Post-transcriptional regulation of chemokine receptor CXCR4 by estrogen in HER2 overexpressing, estrogen receptor-positive breast cancer cells.

Authors:  Surojeet Sengupta; Rachel Schiff; Benita S Katzenellenbogen
Journal:  Breast Cancer Res Treat       Date:  2008-09-19       Impact factor: 4.872

3.  Routine assessment of prognostic factors in breast cancer using a multicore tissue microarray procedure.

Authors:  Anna Sapino; Caterina Marchiò; Rebecca Senetta; Isabella Castellano; Luigia Macrì; Paola Cassoni; Giampiero Ghisolfi; Milena Cerrato; Enrico D'Ambrosio; Gianni Bussolati
Journal:  Virchows Arch       Date:  2006-06-13       Impact factor: 4.064

4.  Prospective multi-centre study to validate chromogenic in situ hybridisation for the assessment of HER2 gene amplification in specimens from adjuvant and metastatic breast cancer patients.

Authors:  Sabine Riethdorf; Bernhard Hoegel; Birgit John; German Ott; Peter Fritz; Susanne Thon; Thomas Loening; Klaus Pantel
Journal:  J Cancer Res Clin Oncol       Date:  2010-04-16       Impact factor: 4.553

5.  18F-FDG PET of locally invasive breast cancer and association of estrogen receptor status with standardized uptake value: microarray and immunohistochemical analysis.

Authors:  Joseph R Osborne; Elisa Port; Mithat Gonen; Ashley Doane; Henry Yeung; William Gerald; Josh B Cook; Steven Larson
Journal:  J Nucl Med       Date:  2010-03-17       Impact factor: 10.057

6.  Invasive lobular carcinoma of the breast with extracellular mucin- a new rare variant.

Authors:  Vaibhav Bhika Bari; Sandhya Unmesh Bholay; Kavita Chandrahas Sane
Journal:  J Clin Diagn Res       Date:  2015-04-01

Review 7.  Overcoming endocrine resistance in metastatic breast cancer: Current evidence and future directions.

Authors:  Andrea Milani; Elena Geuna; Gloria Mittica; Giorgio Valabrega
Journal:  World J Clin Oncol       Date:  2014-12-10

8.  Clinicopathological variables predicting HER-2 gene status in immunohistochemistry-equivocal (2+) invasive breast cancer.

Authors:  Yongling Ji; Liming Sheng; Xianghui Du; Guoqin Qiu; Bo Chen; Xiaojia Wang
Journal:  J Thorac Dis       Date:  2014-07       Impact factor: 2.895

9.  Study of hormone receptors and epidermal growth factor expression in invasive breast cancers in a cohort of Western India.

Authors:  Hardik Dodiya; Amit Patel; Dipal Patel; Ashish Kaushal; D G Vijay
Journal:  Indian J Clin Biochem       Date:  2013-01-03

Review 10.  Towards personalized treatment for early stage HER2-positive breast cancer.

Authors:  Kristina Goutsouliak; Jamunarani Veeraraghavan; Vidyalakshmi Sethunath; Carmine De Angelis; C Kent Osborne; Mothaffar F Rimawi; Rachel Schiff
Journal:  Nat Rev Clin Oncol       Date:  2019-12-13       Impact factor: 66.675

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.